Porton Advanced Partners with Hualong Biological for End-to-End MATC Therapy CDMO Services

• Porton Advanced has partnered with Hualong Biological to provide CDMO services for the development of Multi-Activated T Cell (MATC) therapy.

• The partnership covers process optimisation to regulatory submission to advance MATC into clinical trials.

Porton Advanced, a contract development and manufacturing organisation (CDMO) specialising in advanced therapy medicinal products (ATMPs), has announced a partnership with Hualong Biological to accelerate the development of a novel cell therapy for solid tumours.

The agreement covers end-to-end CDMO services for Hualong’s Multi-Activated T Cell (MATC) therapy, including process optimisation, CMC strategy, GMP manufacturing, and regulatory submission support. The aim is to streamline the therapy’s transition from research to clinical development.

Hualong Biological has conducted multiple investigator-initiated trials (IITs), which have shown promising therapeutic benefits for the MATC platform across a range of solid tumour indications.

Mingguang Huang, Chairman of Hualong Biological, said: “We are delighted to partner with Porton Advanced. Their comprehensive CDMO technical expertise and regulatory experience in cell therapy will significantly enhance our MATC program’s development efficiency and IND preparation timeline.”